BioSpace News Archive

Scholar Rock today announced that management will participate in the following upcoming investor conferences.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology company, today provided a corporate update and reported financial results for the third quarter of 2022.

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced it hired Brendan Carney as National Sales Director.

Equillium, Inc. announced that it will participate in fireside chat presentations at the Stifel Healthcare Conference and the Jefferies London Healthcare Conference.

Genialis is presenting new data and results this week from its biomarker discovery platform, ResponderID TM At the Society for Immunotherapy of Cancer (SITC) annual meeting.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets.

Evolution Optiks Limited, a global leader in light field technology applications, announced today the completion of enrollment of the pivotal U.S. Food and Drug Administration (FDA) clinical study to evaluate the safety and efficacy of its subjective light field LFR-260 tele-phoropter (investigational device).

Notch Therapeutics, Inc. is pleased to welcome new members to its Scientific Advisory Board (SAB).

Longboard Pharmaceuticals, Inc. today announced that members of its senior leadership team will present in a fireside chat format at the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day, which is taking place November 14-15, 2022, in New York City.

PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today announced that it has initiated a Phase 3 trial, HAT-301, as part of its strategic plan to obtain US market approval of PAX-101 (intravenous suramin).